세계 동물용 약물 감수성 검사 시장은 2025-2032년의 예측 기간 동안 5.61%의 연평균 복합 성장률(CAGR)을 나타내고, 2024년 11억 1,000만 달러에서 2032년 17억 2,000만 달러로 성장할 것으로 예측됩니다. 이 시장의 주요 원동력은 주요 수의학 조직의 규제 및 교육 이니셔티브 증가, 항균제 감수성 테스트(AST)에서 인공지능(AI)의 잠재력 증가, 가축 사육두수 증가, 동물의 항균제 내성(AMR) 증가 등의 요인으로 인해 발생합니다.
세계 동물용 약물 감수성 검사(AST) 시장은 동물의 항균제 내성 문제 증가와 올바른 항생제 투여에 대한 인식 확대에 따라 꾸준히 성장하고 있습니다. AST 프로세스는 가축과 반려동물 모두에게 적절한 세균 감염 치료법을 선택하기 위해 수의사에게 필수적인 정보를 제공하여 항균제의 오남용을 줄일 수 있습니다. 이 방법은 동물의 건강과 인간의 건강, 그리고 환경의 건강 사이의 강력한 연결고리를 구축함으로써 세계 원헬스(One Health)의 원칙을 따르고 있습니다. 수의학적 진단 분야는 규제 강화와 수의사 전문가 및 AST 서비스를 원하는 반려동물 보호자들의 인식이 높아지면서 성장세를 보이고 있습니다. 동물용 표준검사실은 진료소 및 병원과 함께 치료 성공률을 높이고 항균제 내성을 예방하기 위한 표준 진단 절차로 AST 검사를 사용하고 있습니다. 신속한 진단 접근법 및 인공지능 평가 시스템과 함께 자동 검사 장비를 도입하여 검사 절차의 정확성과 속도를 향상시키고 있습니다. 시장은 동물의료시설이 계속 발전하는 한편, 상당수의 동물이 사육되고 있는 지역에서 강세를 보이고 있습니다. 항균제 스튜어드십을 장려하는 정부 프로그램과 수의학 의료에 대한 재정 지원을 통해 시장이 확대되고 있습니다. 수의용 AST 시장은 고가의 검사 비용과 지방의 검사 제한 등의 장애물에 직면해 있지만, 규제 프레임워크와 세계 보건 목표와 함께 기술 발전이 이루어지고 있어 향후 강력한 성장 잠재력을 보여주고 있습니다.
예를 들어, 2023년 9월, FAO 몽골은 21개 주에서 50명 이상의 수의학 검사 분석가를 훈련시켜 잔류 항생제 및 항균제 내성을 검출할 수 있도록 했습니다. 이번 교육은 ACT 및 MPTF 프로젝트의 일환으로 실시되었으며, 실습과 이론에 기반한 학습을 통해 식품 안전과 공중 보건을 강화하는 것을 목표로 하고 있습니다. 이러한 프로그램은 동물용 약물 감수성 검사 시장 수요를 증가시킬 것입니다.
대상이 되는 모든 지역과 국가에 대해 모든 부문이 제공됩니다.
위에 언급된 회사는 시장 점유율에 따른 순위를 보유하지 않으며, 조사 작업 중 이용 가능한 정보에 따라 변경될 수 있습니다.
Global veterinary antimicrobial susceptibility testing market is projected to witness a CAGR of 5.61% during the forecast period 2025-2032, growing from USD 1.11 billion in 2024 to USD 1.72 billion in 2032. The market is primarily driven by factors like rising regulatory and training initiatives among leading veterinary organizations, the growing potential of artificial intelligence (AI) in antimicrobial susceptibility testing (AST), the rising livestock population, and growing antimicrobial resistance (AMR) among animals.
Global veterinary antimicrobial susceptibility testing (AST) market is growing steadily because of rising animal antimicrobial resistance issues and expanding awareness about correct antibiotic practices. The process of AST provides essential information for veterinary professionals to select proper bacterial infection treatments in both livestock and companion animals, which reduces antimicrobial misuse. The method follows worldwide One Health principles by establishing strong links between animal health and human health and environmental health. The veterinary diagnostic sector experiences growth because of stricter regulations and rising awareness among veterinary professionals and pet owners who seek AST services. Veterinary reference laboratories, together with clinics and hospitals, use AST testing as a standard diagnostic procedure to improve treatment success rates and prevent antimicrobial resistance. The implementation of automated testing devices along with quick diagnostic approaches and artificial intelligence evaluation systems has enhanced the precision and speed of testing procedures. The market shows increasing strength in regions that maintain substantial animal numbers while veterinary facilities continue to develop. The market expands through government programs that encourage antimicrobial stewardship and veterinary healthcare funding. The veterinary AST market demonstrates robust future growth potential because of technological advancements alongside regulatory frameworks and worldwide health objectives, although it faces obstacles from expensive testing and rural testing restrictions.
For instance, in September 2023, FAO Mongolia trained over 50 veterinary laboratory analysts in 21 provinces to detect antibiotic residues and antimicrobial resistance. The training is identified as part of the ACT and MPTF projects, intended to strengthen food safety and public health through practical and theory-based learning. Such programs boost the demand for the veterinary antimicrobial susceptibility testing market.
Rising Prevalence of Antimicrobial Resistance Boosts Market Demand
The increasing occurrence of antimicrobial resistance (AMR) in animals represents a primary factor that escalates the need for veterinary antimicrobial susceptibility testing (AST). Excessive and incorrect use of antibiotics in livestock and companion animals has produced bacteria that resist treatment, leading to difficult medical interventions and increased disease transmission potential. The increasing resistance of pathogens endangers animal well-being and generates major public health threats because these resistant pathogens can reach humans through direct animal interactions or food consumption. Veterinary AST enables veterinarians to select the best antimicrobial drugs that specifically address certain infections, thus providing them with data to deliver precise treatments. Veterinary professionals together with farmers and pet owners and regulatory agencies, now focus more heavily on responsible antibiotic practices because of their growing awareness of AMR. Stewardship programs mandated or suggested by governments and international health organizations require veterinary providers to conduct AST before making antibiotic prescriptions. The new medical approach has led to a substantial rise in the adoption of AST services which drives overall market expansion.
For instance, in February 2024, Avails Medical secured FDA 510(k) clearance for the eQUANT system, a rapid, automated device for antibiotic susceptibility testing. eQUANT standardizes the inoculum from positive blood cultures such that it reduces routine AST turnaround times by as much as one day and facilitates earlier and more effective targeted antibiotic therapy.
Technological Advancement in Diagnostic Testing Fuels Market Growth
Technological advancements in diagnostics are certainly propelling growth in the veterinary antimicrobial susceptibility testing (AST) market. The traditional manual testing approach works effectively but requires extensive time and causes human mistakes to occur. Modern diagnostic technologies, including automated AST systems as well as microfluidic devices and rapid molecular assays, and AI-powered platforms, produce fast, precise, and dependable testing outcomes. The new technologies enable veterinary professionals and diagnostic labs to detect pathogens quickly while determining optimal antimicrobial agents, which leads to precise and prompt treatment choices. Automated processes decrease work intensity while producing consistent outcomes, and microfluidics combined with PCR-based methods transform diagnostic turnaround times from multiple days to a few hours. The advanced diagnostic systems offer the ability to detect multiple resistance genes simultaneously within a single test, which improves the overall testing efficiency. The integration of AI technology enables data interpretation, trend analysis, and surveillance reporting, which leads to more accessible and actionable diagnostics. Veterinary practices and reference labs requiring improved productivity and antimicrobial stewardship guideline compliance drive the growing demand for advanced diagnostic tools, which expands the AST market worldwide.
For instance, in June 2023, Sysmex Corporation released a ground-breaking point-of-care system for the rapid antimicrobial susceptibility testing of urine samples in only 30 minutes in Europe. This innovation tackles urinary tract infections while supporting infection control for reducing antimicrobial resistance in clinical settings.
Veterinary Reference Laboratory Holds Largest Market Share
The veterinary antimicrobial susceptibility testing (AST) market shows its largest market share in veterinary reference laboratories because they maintain advanced infrastructure and handle high testing volumes while serving as diagnostic hubs. These laboratories maintain high-throughput automated testing systems that deliver precise and rapid antimicrobial testing for all animal species. The laboratories serve veterinary clinics, hospitals, farms, and academic institutions through large diagnostic sample processing while implementing standard testing protocols. The laboratories receive complex cases for processing while participating in antimicrobial resistance surveillance programs and delivering fast turnaround times, thus making them the preferred providers of AST services. Reference labs maintain strict quality control standards and employ skilled personnel, which results in producing reliable results. In addition, partnerships with regulators and researchers put them in an advantageous position in antimicrobial stewardship. As antibiotic therapies that target diseases increase in demand, veterinary reference laboratories continue to take the lead in both services rendered and technology adoption.
North America Dominates the Veterinary Antimicrobial Susceptibility Testing Market
North America holds a dominant position in the veterinary antimicrobial susceptibility testing (AST) market because of its superior animal health facilities, together with its robust regulatory system. The area has a relatively high level of awareness of antimicrobial resistance and the significance of targeted antibiotic use among veterinarians and animal health professionals. This high level of awareness has resulted in an increased adoption of AST in veterinary and consultant veterinary clinics, hospitals, and reference laboratories. The United States leads the market through its established surveillance networks and government antimicrobial stewardship programs, and funding for diagnostic technology development. The FDA and USDA use regulatory frameworks to advance animal antibiotic stewardship by pushing veterinary professionals toward AST testing for treatment decisions. The market receives additional support from the expanding pet population, together with growing livestock operations and rising animal health expenditures.
For instance, in January 2024, the American Veterinary Medical Association (AVMA) released six documents on animal antimicrobial susceptibility testing, providing veterinary professionals with guidance on selecting antimicrobial therapy and predicting outcomes for a range of antimicrobial agents in bacterial infections.
Impact of U.S. Tariffs on Veterinary Antimicrobial Susceptibility Testing Market
The veterinary antimicrobial susceptibility testing market faces substantial effects from U.S. tariffs on diagnostic equipment and raw materials imported from manufacturing centers, including China. Tariffs lead to increased prices of crucial instruments, together with consumables such as culture media, along with testing panels and automated systems that need importing.
The increased costs may affect veterinary clinics, together with laboratories and end-users, by decreasing the usage of advanced AST technologies, especially in practices with limited budgets. Veterinary facilities with limited resources may postpone their equipment replacements or choose manual testing methods, which result in decreased diagnostic precision and longer testing periods.
Trade policy uncertainties create supply chain disruptions, which cause inventory shortages and restrict access to premium testing components. Domestic production growth may occur as a reaction to tariffs, but it does not immediately balance out the shortfall or pricing effects.
The implementation of tariffs creates financial obstacles that could hold back market growth and slow down technological adoption in the United States' veterinary antimicrobial susceptibility testing systems.
Key Players Landscape and Outlook
The competitive landscape of the veterinary antimicrobial susceptibility market is characterized by innovation along with worldwide expansion and strategic partnerships. The main players develop modern diagnostic technologies that include automated systems and rapid molecular assays to improve both speed and precision of their testing processes. R&D investments, along with partnerships between research institutions and veterinary organizations, help these companies build stronger market positions. Their growth strategies depend on entering developing markets and providing affordable and scalable solutions. The market will experience increased competition because companies strive to meet growing demand which stems from worldwide antimicrobial resistance issues and regulatory requirements.
In June 2023, bioMerieux SA earned nine clinical laboratory IMV ServiceTrak awards, a significant achievement. These awards recognized the company's excellence across five markets, including Immunoassay, ID/AST, and Blood Culture, further underscoring its commitment to high-quality diagnostics solutions and its leadership position in the clinical laboratory market.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.